Gasdermin‐ B ( GSDMB ) takes center stage in antibacterial defense, inflammatory diseases, and cancer
The FEBS Journal · 2024-07 · 291 (14) · 3060-3071
DOI: 10.1111/febs.17018 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The FEBS Journal, online erschienen am 06.12.2023. Verfasst von David Sarrio und 2 weiteren Autor:innen. Beteiligte Einrichtung: Biochemistry Department, Instituto de Investigaciones Biomédicas "Alberto Sols" (IIBm-CISC), Conexión Cáncer (UAM-CSIC), Universidad Autónoma de Madr…. Hauptthemen laut MEDLINE: Neoplasms, Inflammation, Pyroptosis. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fundación Científica Asociación Española Contra el Cáncer, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, AEI.
Abstract (Originalsprache)
One of the hottest topics in biomedical research is to decipher the functional implications of the Gasdermin (GSDM) protein family in human pathologies. These proteins are the key effectors of a lytic and pro‐inflammatory cell death type termed pyroptosis (also known as “Gasdermin‐mediated programmed cell death”). However, ever‐growing evidence showed that GSDMs can play multiple and complex roles in a context‐dependent manner. In this sense, Gasdermin‐B (GSDMB; the only GSDM gene absent in mice and rats) has been implicated in antibacterial defense, numerous inflammatory pathologies (e.g., asthma, ulcerative colitis), and cancer, but both cell death‐dependent and ‐independent functions have been reported in these diseases, fueling the debate on whether GSDMB has genuine pyroptotic capacity. Recently, a series of seminal papers cast light on the GSDMB multitasking capacity by showing that different GSDMB transcriptional isoforms have distinct biological activities. Nonetheless, there are still obscure areas to be clarified on the precise functional involvement of GSDMB translated variants in physiological and pathological conditions. In this viewpoint, we critically discuss the most recent and exciting data on this topic and propose a series of relevant challenges that need to be overcome before GSDMB‐driven biomedical applications (as a biomarker of disease risk/progression/outcome or as specific therapeutic target) become a reality in clinical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biochemistry Department, Instituto de Investigaciones Biomédicas "Alberto Sols" (IIBm-CISC), Conexión Cáncer (UAM-CSIC), Universidad Autónoma de Madrid (UAM), Spain.
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.
- Fundación MD Anderson Internacional, Madrid, Spain.
ORCID-Profile: David Sarrio, Gema Moreno-Bueno
Förderung
- Fundación Científica Asociación Española Contra el Cáncer
- Instituto de Salud Carlos III
- Ministerio de Ciencia e Innovación, AEI
- Ministerio de Ciencia e Innovación
Zitieren
APA
Sarrio, D., Colomo, S., & Moreno-Bueno, G. (2024). Gasdermin‐ B ( GSDMB ) takes center stage in antibacterial defense, inflammatory diseases, and cancer. The FEBS Journal, 291(14), 3060-3071. https://doi.org/10.1111/febs.17018
Vancouver
Sarrio D, Colomo S, Moreno-Bueno G. Gasdermin‐ B ( GSDMB ) takes center stage in antibacterial defense, inflammatory diseases, and cancer. The FEBS Journal. 2024;291(14):3060-3071. doi:10.1111/febs.17018
BibTeX
@article{Sarrio2024,
author = {Sarrio, David and Colomo, Sara and Moreno-Bueno, Gema},
title = {Gasdermin‐ B ( GSDMB ) takes center stage in antibacterial defense, inflammatory diseases, and cancer},
journal = {The FEBS Journal},
year = {2024},
volume = {291},
number = {14},
pages = {3060--3071},
doi = {10.1111/febs.17018}
}
EUVIMED